C-X-C Chemokine Receptor Type 4 (CXCR4) and Programmed Death-Ligand 1 (PD-L1) Expression are Prognostic Biomarkers for Papillary Thyroid Carcinoma

被引:0
|
作者
Ding, Ting [1 ]
Song, Qian [1 ]
Xu, Yanjun [2 ]
Liu, Qiya [3 ]
机构
[1] Huanggang Cent Hosp, Dept Endocrinol, Huanggang City 438021, Hubei, Peoples R China
[2] Zhejiang Univ Tradit Chinese Med, Dept Special Inspect Sect, Affiliated Hosp 3, Hangzhou 310014, Zhejiang, Peoples R China
[3] Sha He Hosp Chang Ping Dist Beijing, Dept Gen Med, Beijing 100005, Peoples R China
关键词
CXCR4; PD-L1; Papillary Thyroid Carcinoma; Survival Analysis; CANCER; SURVIVAL; NIVOLUMAB; ANTITUMOR; PATHWAY;
D O I
10.1166/jbt.2022.2987
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Chemokines and immunomodulatory factors involve in tumor development. Papillary thyroid carcinoma (PTC) is considered to start from dendritic cell infiltration and then produce immunomodulatory factors. In this study, CXCR4 and PD-L1 biomarkers were used to explore their prognostic role in PTC survival. Confocal microscopy detected the transfection efficiency in tumor cells. 42 PTC patients and thyroiditis patients (control) were enrolled to measure the expressions of CXCR4 and PD-L1. Multi-factor analysis analyzed the effect of combined CXCR4 and PD-L1 expression on ROC. The two groups had no differences in the baseline characteristics. CTXCR4 and PD-L1 level in PTC patients was significantly higher than control. CXCR4 was lowly expressed in thyroid cancer tissue and PD-L1 was highly expressed in serological samples. Compared with single measurement, the combined detection of CXCR4 and PD-L1 showed more ROC area. In conclusion, reduced CXCR4 and increased PD-L1 levelis found in thyroid cancer and their level might be used IP: 182.75.148.10 On: Thu, 20 Jan 2022 10:55:44 as predictive markers for PTtoCopyright:improve thAmeriancurative Scintificeffect. Publishers
引用
收藏
页码:953 / 957
页数:5
相关论文
共 50 条
  • [41] Programmed Cell Death-Ligand 1 (PD-L1) Immunohistochemical Expression in Equine Melanocytic Tumors
    Pimenta, Jose
    Prada, Justina
    Pires, Isabel
    Cotovio, Mario
    ANIMALS, 2024, 14 (01):
  • [42] Prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with stage III colorectal cancer.
    Koganemaru, Shigehiro
    Inoshita, Naoko
    Miura, Yuji
    Fukui, Yudai
    Ozaki, Yukinori
    Tomizawa, Kenji
    Hanaoka, Yutaka
    Toda, Shigeo
    Suyama, Koichi
    Tanabe, Yuko
    Moriyama, Jin
    Fujii, Takeshi
    Matoba, Shuichiro
    Kuroyanagi, Hiroya
    Takano, Toshimi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases
    Drolaiz H. W. Liu
    Heike I. Grabsch
    Beat Gloor
    Rupert Langer
    Bastian Dislich
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 13345 - 13352
  • [44] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN UTERINE GRADE 3 ENDOMETRIOID ADENOCANCER
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Guzel, A. B.
    Khatib, G.
    Seydaoglu, G.
    Vardar, M. A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1126 - 1126
  • [45] Evaluation of C-X-C chemokine receptor type 4 (CXCR4) and Peroxisome proliferator-activated receptor gamma (PPAR-γ) expression in colorectal carcinoma: Relation to the available clinicopathological parameters
    Bedeer, Asmaa E.
    Heabah, Nehal El-Ghaffar
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2023, 66 (03) : 465 - 471
  • [46] Clinicopathological significance of chemokine receptor CXCR4 expression in papillary thyroid carcinoma: a meta-analysis
    Wu, Zhaoshu
    Cao, Yue
    Jiang, Xiaoyan
    Li, Min
    Wang, Gang
    Yang, Yue
    Lu, Kai
    MINERVA ENDOCRINOLOGICA, 2020, 45 (01) : 43 - 48
  • [47] Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma
    Ilaria Girolami
    Liron Pantanowitz
    Ozgur Mete
    Matteo Brunelli
    Stefano Marletta
    Chiara Colato
    Pierpaolo Trimboli
    Anna Crescenzi
    Massimo Bongiovanni
    Mattia Barbareschi
    Albino Eccher
    Endocrine Pathology, 2020, 31 : 291 - 300
  • [48] Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma
    Girolami, Ilaria
    Pantanowitz, Liron
    Mete, Ozgur
    Brunelli, Matteo
    Marletta, Stefano
    Colato, Chiara
    Trimboli, Pierpaolo
    Crescenzi, Anna
    Bongiovanni, Massimo
    Barbareschi, Mattia
    Eccher, Albino
    ENDOCRINE PATHOLOGY, 2020, 31 (03) : 291 - 300
  • [49] Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma
    An, Hyo Jung
    Ko, Gyung Hyuck
    Lee, Jeong-Hee
    Lee, Jong Sil
    Kim, Dong Chul
    Yang, Jung Wook
    Kim, Min Hye
    Kim, Jin Pyeong
    Jung, Eun Jung
    Song, Dae Hyun
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2018, 52 (01) : 9 - 13
  • [50] MEK1/2 inhibitor inhibits neointima formation by activating miR-126-3p/C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 4 (CXCR4) axis
    Yan, Yali
    Zhu, Mengmeng
    Ma, Jialing
    He, Xiaoyu
    Yang, Xiaoxiao
    Xu, Hongmei
    Jiang, Meixiu
    Zhang, Shuang
    Duan, Yajun
    Han, Jihong
    Chen, Yuanli
    BIOENGINEERED, 2022, 13 (04) : 11214 - 11227